NLS Pharmaceutics (NLSP) Competitors $2.28 -0.11 (-4.60%) Closing price 04:00 PM EasternExtended Trading$2.28 +0.01 (+0.22%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NLSP vs. RVPH, MDCX, OKUR, MAAQ, ONCY, CLNN, PLUR, FBLG, KPTI, and LTRNShould you be buying NLS Pharmaceutics stock or one of its competitors? The main competitors of NLS Pharmaceutics include Reviva Pharmaceuticals (RVPH), Medicus Pharma (MDCX), OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), Oncolytics Biotech (ONCY), Clene (CLNN), Pluri (PLUR), FibroBiologics (FBLG), Karyopharm Therapeutics (KPTI), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. NLS Pharmaceutics vs. Its Competitors Reviva Pharmaceuticals Medicus Pharma OnKure Therapeutics Mana Capital Acquisition Oncolytics Biotech Clene Pluri FibroBiologics Karyopharm Therapeutics Lantern Pharma NLS Pharmaceutics (NASDAQ:NLSP) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment. Does the MarketBeat Community believe in NLSP or RVPH? Reviva Pharmaceuticals received 23 more outperform votes than NLS Pharmaceutics when rated by MarketBeat users. Likewise, 91.18% of users gave Reviva Pharmaceuticals an outperform vote while only 57.14% of users gave NLS Pharmaceutics an outperform vote. CompanyUnderperformOutperformNLS PharmaceuticsOutperform Votes857.14% Underperform Votes642.86% Reviva PharmaceuticalsOutperform Votes3191.18% Underperform Votes38.82% Do analysts prefer NLSP or RVPH? Reviva Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 1,139.16%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than NLS Pharmaceutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Is NLSP or RVPH more profitable? Company Net Margins Return on Equity Return on Assets NLS PharmaceuticsN/A N/A N/A Reviva Pharmaceuticals N/A N/A -252.53% Does the media refer more to NLSP or RVPH? In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. Reviva Pharmaceuticals' average media sentiment score of 0.93 beat NLS Pharmaceutics' score of 0.44 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment NLS Pharmaceutics Neutral Reviva Pharmaceuticals Positive Which has stronger valuation & earnings, NLSP or RVPH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNLS PharmaceuticsN/AN/A-$12.17MN/AN/AReviva PharmaceuticalsN/AN/A-$39.26M-$0.79-0.92 Which has more volatility & risk, NLSP or RVPH? NLS Pharmaceutics has a beta of 0.05, indicating that its share price is 95% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Do insiders & institutionals believe in NLSP or RVPH? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryReviva Pharmaceuticals beats NLS Pharmaceutics on 10 of the 12 factors compared between the two stocks. Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NLSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NLSP vs. The Competition Export to ExcelMetricNLS PharmaceuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.20M$6.85B$5.56B$8.50BDividend YieldN/A2.53%5.28%4.16%P/E RatioN/A8.4326.6419.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / BookN/A6.536.974.60Net Income-$12.17M$143.25M$3.23B$248.06M7 Day Performance-0.87%0.21%-0.98%-1.03%1 Month Performance39.87%10.92%7.70%3.50%1 Year Performance1,862.13%2.44%31.32%12.68% NLS Pharmaceutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NLSPNLS PharmaceuticsN/A$2.28-4.6%N/A+1,819.7%$8.20MN/A0.006Short Interest ↑Gap DownRVPHReviva Pharmaceuticals2.7394 of 5 stars$0.85+2.9%$9.00+965.1%-48.3%$39.50MN/A-0.765News CoverageMDCXMedicus Pharma1.9647 of 5 stars$2.88+4.3%$23.50+716.0%N/A$39.09MN/A0.00N/ANews CoverageHigh Trading VolumeOKUROnKure Therapeutics3.3384 of 5 stars$2.87-0.3%$32.33+1,026.6%N/A$38.77MN/A-0.24N/ANews CoverageGap UpMAAQMana Capital AcquisitionN/A$4.77+5.4%N/A+605.7%$38.72MN/A0.001Gap DownONCYOncolytics Biotech1.4752 of 5 stars$0.44+23.6%$4.33+874.2%-44.0%$38.51MN/A-1.6530High Trading VolumeCLNNClene2.5356 of 5 stars$4.22-0.7%$40.00+847.9%-50.7%$37.91M$350K-0.80100Short Interest ↑PLURPluri2.2556 of 5 stars$4.39-7.6%$12.00+173.3%-24.8%$37.21M$1.03M-0.78150Short Interest ↑FBLGFibroBiologics3.2642 of 5 stars$0.94-1.2%$13.00+1,276.0%-88.6%$36.58MN/A-4.5010KPTIKaryopharm Therapeutics4.0199 of 5 stars$4.21-6.2%$43.20+926.1%-71.8%$36.37M$142.13M-4.13380Gap DownLTRNLantern Pharma2.5565 of 5 stars$3.37+1.5%$25.00+641.8%-42.8%$36.35MN/A-1.8920Insider Trade Related Companies and Tools Related Companies Reviva Pharmaceuticals Alternatives Medicus Pharma Alternatives OnKure Therapeutics Alternatives Mana Capital Acquisition Alternatives Oncolytics Biotech Alternatives Clene Alternatives Pluri Alternatives FibroBiologics Alternatives Karyopharm Therapeutics Alternatives Lantern Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NLSP) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NLSP Stock Free NLSP Stock Alerts